Johnson & Johnson reports 9.1% increase in sales for Q4 2025

Johnson & Johnson (J&J) has reported a 9.1% increase in sales for Q4 2025, reaching $24.56bn, with net earnings rising by 49.1% to $5.11bn. For the entire year, sales grew by 6% to $94.2bn, and full-year earnings per share (EPS) registered at $11.03. The diluted earnings per share (EPS) for Q4 2025 stood at $2.10, up from $1.41 in Q4 2024, reflecting a 48.9% growth. Additionally, the adjusted net earnings were reported at $6.1bn, up by 21.5% from $4.94bn in the same period of the prior year. Adjusted d ...